The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes
Abstract
AIM: Metformin therapy reduces microvascular complications in Type 2 diabetes; questions remain, however, regarding its impact on macrovascular events. This study examined metformin use in relation to risk of cardiovascular-related hospitalization and mortality. METHODS: We conducted a retrospective cohort analysis, using Saskatchewan Health administrative databases to identify new users of oral antidiabetic drugs. Subject groups were defined by medication use during 1991-1999: sulphonylurea monotherapy, metformin monotherapy, or combination therapy. Deaths and non-fatal hospitalizations recorded during the study period were identified as cardiovascular-related from ICD-9 codes. The main outcome was a composite of first non-fatal hospitalization or death. Standard multivariate techniques, including propensity scores, were used to adjust for potential confounding. Multivariate Cox proportional hazard models were used to examine the relationship between metformin use and the composite endpoint. RESULTS: Metformin monotherapy was associated with a lower risk of the composite endpoint (adjusted hazard ratio 0.81; 95% confidence interval 0.68, 0.97) compared with sulphonylurea monotherapy. Combination therapy with meformin and a sulphonylurea was associated with lower mortality, but had similar hospitalization rates, to sulphonylurea monotherapy. CONCLUSIONS: Metformin monotherapy was associated with a lower risk of cardiovascular-related morbidity and mortality, and combination metformin and sulphonylurea therapy was associated with a reduced risk of fatal cardiovascular events, when compared with sulphonylurea monotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Johnson et al. accessed the Saskatchewan Health Administrative databases for a retrospective study and also reported reduced cardiovascular morbidity and mortality benefits of metformin monotherapy versus sulfonylurea monotherapy (31).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [31]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. V. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 3,104
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Invited commentary: propensity scores.
Joffe, M., & Rosenbaum, P. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010011 · Cited by 1,117
Research works printed but not linked: 1
- Tsuyuki RT, 1999, Nitroglycerin as an indicator for the presence of coronary heart disease, Can Pharmaceut J, 132, 32
Cited by
Sorted by citations
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,131
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440
Guidelines for the management of chronic kidney disease
Levin, A., Hemmelgarn, B. R., Culleton, B. F., Tobe, S. W., McFarlane, P., Ruzicka, M., Burns, K. D., Manns, B., White, C., Madore, F., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080351 · Cited by 428
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 401
Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356
Justice, J. N., Ferrucci, L., Newman, A. B., Aroda, V. R., Bahnson, J. L., Divers, J., Espeland, M. A., Marcovina, S., Pollak, M. N., Kritchevsky, S. B., et al. (2018) · GeroScience · doi:10.1007/s11357-018-0042-y · Cited by 359
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
Repurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R. S., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 300
Metformin as Anti-Aging Therapy: Is It for Everyone?
Soukas, A. A., Hao, H., & Wu, L. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.07.015 · Cited by 266
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
Simpson, S. H. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050748 · Cited by 235
“Findings from the UKPDS and other investigations, including our previous studies, suggest that strategies that do not use sulfonylureas may be associated with different rates of death and cardiovascular events.(15,16,20,21) This variation may be caused by differences in patient characteristics or the pharmacologic pro…”
ResultRao, A. D., Kuhadiya, N. D., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Qaseem, A., Barry, M. J., Humphrey, L. L., & Forciea, M. A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-1860 · Cited by 211
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
Palikaras, K., Daskalaki, I., Markaki, M., & Tavernarakis, N. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.04.005 · Cited by 181
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 153
Metformin and ageing: improving ageing outcomes beyond glycaemic control
Valencia, W. M., Palacio, A., Tamariz, L., & Florez, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4349-5 · Cited by 142
Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes
Bailey, C. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6092-0 · Cited by 138
Pantalone, K. M., Hobbs, T. M., Wells, B. J., Kong, S. X., Kattan, M. W., Bouchard, J. R., Yu, C., Sakurada, B., Milinovich, A., Weng, W., et al. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000093 · Cited by 137
Monami, M., Luzzi, C., Lamanna, C., Chiasserini, V., Addante, F., Desideri, C. M., Masotti, G., Marchionni, N., & Mannucci, E. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.642 · Cited by 114
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.736 · Cited by 111
Lee, C. G., Heckman‐Stoddard, B. M., Dabelea, D., Gadde, K. M., Ehrmann, D. A., Ford, L., Prorok, P. C., Boyko, E. J., Pi-Sunyer, X., Wallia, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1046 · Cited by 101
Modulating Mitophagy in Mitochondrial Disease
Dombi, E., Mortiboys, H., & Poulton, J. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170616101741 · Cited by 100
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 98
Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Correia, S. C., Carvalho, C., Santos, M. S., Seiça, R. M. F., Oliveira, C. R., & Moreira, P. I. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708786369546 · Cited by 98
Eurich, D. T., Simpson, S. H., Senthilselvan, A., Asche, C. V., Sandhu-Minhas, J. K., & McAlister, F. A. (2013) · BMJ · doi:10.1136/bmj.f2267 · Cited by 93
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
Duong, J. K., Furlong, T. J., Roberts, D. M., Graham, G. G., Greenfield, J. R., Williams, K. M., & Day, R. O. (2013) · Drug Safety · doi:10.1007/s40264-013-0038-6 · Cited by 91
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 89
Variations in tissue selectivity amongst insulin secretagogues: a systematic review
Abdelmoneim, A. S., Hasenbank, S., Seubert, J. M., Brocks, D. R., Light, P. E., & Simpson, S. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01496.x · Cited by 88
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2010) · Diabetes Care · doi:10.2337/dc10-0017 · Cited by 87
Forst, T. M., Hanefeld, M., Jacob, S., Moeser, G., Schwenk, G., Pfützner, A., & Haupt, A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112465442 · Cited by 86
Neven, E., Vervaet, B. A., Brand, K. M. G., Gottwald‐Hostalek, U., Opdebeeck, B., Maré, A. D., Verhulst, A., Lalau, J., Kamel, S., Broe, M. E. D., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.027 · Cited by 81
Translating the Science of Aging into Therapeutic Interventions
Kirkland, J. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025908 · Cited by 78
Guzmán, J. R., Lyra, R., Aguilar-Salinas, C. A., Cavalcanti, S. M., Escaño, F., Tambasia, M., & Duarte, E. D. R. (2010) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892010001200008 · Cited by 75
Araki, A., Iimuro, S., Sakurai, T., Umegaki, H., Iijima, K., Nakano, H., Oba, K., Yokono, K., Sone, H., Yamada, N., et al. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00808.x · Cited by 72
AMP-Activated Protein Kinase Regulates E3 Ligases in Rodent Heart
Baskin, K. K., & Taegtmeyer, H. (2011) · Circulation Research · doi:10.1161/circresaha.111.252742 · Cited by 71
Froldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 75
Cardiovascular impact of drugs used in the treatment of diabetes
Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 67
Li, Y., Ryu, C. L., Munie, M., Noorulla, S., Rana, S., Edwards, P. A., Gao, H., & Qiao, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/2801450 · Cited by 68
Hu, M., Ye, P., Liao, H., Chen, M., & Yang, F. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2961954 · Cited by 65
Regulation of Hyaluronan Synthesis in Vascular Diseases and Diabetes
Moretto, P., Karousou, E. G., Viola, M., Caon, I., D’Angelo, M. L., Luca, G. D., Passi, A. G., & Vigetti, D. (2015) · Journal of Diabetes Research · doi:10.1155/2015/167283 · Cited by 67
Sottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 65
Diabetic cardiomyopathy: signaling defects and therapeutic approaches
Dobrin, J. S., & Lebeche, D. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.17 · Cited by 63
Epigenetics in extracellular matrix remodeling and hyaluronan metabolism
Vigetti, D., Viola, M., Karousou, E. G., Deleonibus, S., Καραμάνου, Κ., Luca, G. D., & Passi, A. G. (2014) · FEBS Journal · doi:10.1111/febs.12938 · Cited by 62
Explaining the Decline in Early Mortality in Men and Women With Type 2 Diabetes
Charlton, J., Latinovic, R., & Gulliford, M. C. (2008) · Diabetes Care · doi:10.2337/dc08-0137 · Cited by 60
Patorno, E., Patrick, A. R., Garry, E. M., Schneeweiß, S., Gillet, V. G., Bartels, D. B., Massó-González, E. L., & Seeger, J. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3364-z · Cited by 60
Speirs, C., Williams, J. J. L., Riches‐Suman, K., Salt, I. P., & Palmer, T. M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.001 · Cited by 61
Metformin as a Potential Agent in the Treatment of Multiple Sclerosis
Dziedzic, A., Saluk, J., Miller, E. D., & Bijak, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175957 · Cited by 62
Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function
Deng, M., Su, D., Xu, S., Little, P. J., Feng, X., Tang, L., & Shen, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00635 · Cited by 58
Kahler, K. H., Rajan, M., Rhoads, G. G., Safford, M. M., Demissie, K., Lu, S., & POGACH, L. M. (2007) · Diabetes Care · doi:10.2337/dc06-2272 · Cited by 58
Molavi, B., Rassouli, N., Bagwe, S., & Rasouli, N. (2007) · PubMed · Cited by 61
Soraya, H., Farajnia, S., Khani, S., Rameshrad, M., Khorrami, A., Banani, A., Maleki‐Dizaji, N., & Garjani, A. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.10.014 · Cited by 55
Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025098 · Cited by 53
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease
Fisman, E. Z., & Tenenbaum, A. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-38 · Cited by 52
Diot, A., Hinks-Roberts, A., Lodge, T., Liao, C., Dombi, E., Morten, K., Brady, S., Fratter, C., Carver, J. G., Muir, R., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.014 · Cited by 52
Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
Sportelli, C., Urso, D., Jenner, P. G., & Chaudhuri, К. R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00556 · Cited by 47
Sharma, S., Venkatesan, V., Prakhya, B. M., & Bhonde, R. R. (2014) · Mutagenesis · doi:10.1093/mutage/geu086 · Cited by 41
Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus
Johansen, O. E., & Birkeland, K. I. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707050-00002 · Cited by 41
Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice
Cha, H.-N., Choi, J. H., Kim, Y., Kim, J., Ahn, M.-W., & Park, S. (2010) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2010.14.6.377 · Cited by 39
Sillars, B. A., Davis, W. A., Hirsch, I. B., & Davis, T. M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01230.x · Cited by 39
Metformin (dimethyl-biguanide) induced DNA damage in mammalian cells
Amador, R. R., Longo, J. P. F., Lacava, Z. G. M., Dórea, J. G., & Santos, M. D. F. M. A. (2011) · Genetics and Molecular Biology · doi:10.1590/s1415-47572011005000060 · Cited by 37
Diagnosis and Treatment of Diabetic Kidney Disease
Gosmanov, A. R., Wall, B. M., & Gosmanova, E. O. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000185 · Cited by 38
Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus
Koski, R. R. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706294260 · Cited by 36
Stabilization of high-risk plaques
Takata, K., Imaizumi, S., Zhang, B., Miura, S., & Saku, K. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.10.03 · Cited by 40
Lexis, C. P. H., van der Horst‐Schrivers, A. N. A., Lipšic, E., Valente, M. A. E., Kobold, A. C. M., de Boer, R. A., van Veldhuisen, D. J., van der Harst, P., & van der Horst, I. C. C. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000090 · Cited by 34
Wilson, J. M., Farley, K. X., Broida, S. E., Bradbury, T. L., & Guild, G. N. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.01535 · Cited by 33
Corrao, G., Romio, S., Zambon, A., Merlino, L. G., Bosi, E., & Scavini, M. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0939-6 · Cited by 31
Azoulay, L., Schneider‐Lindner, V., Dell’Aniello, S., Schiffrin, A., & Suissa, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1834 · Cited by 31
Composite endpoints in trials of type‐2 diabetes
Einarson, T. R., Garg, M., Kaur, V., & Hemels, M. E. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12226 · Cited by 30
Fonseca, V. A., Bakris, G. L., Bell, D. S. H., McGill, J. B., Raskin, P., Messerli, F. H., Phillips, R. A., Katholi, R. E., Wright, J. T., Waterhouse, B. R., et al. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02151.x · Cited by 29
Tain, Y., Wu, K. L. H., Lee, W., Leu, S., & Chan, J. Y. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041066 · Cited by 30
Sulistio, M. S., Carothers, C., Mangat, M., Lujan, M., OLIVEROS, R. A., & CHILTON, R. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0015-9 · Cited by 25
Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
Buckingham, R. E., & Hanna, A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00700.x · Cited by 26
Metformin strongly affects transcriptome of peripheral blood cells in healthy individuals
Briviba, M., Silamiķelis, I., Kalniņa, I., Ansone, L., Rovīte, V., Elbere, I., Radoviča-Spalviņa, I., Frīdmanis, D., Aladyeva, E., Konrāde, I., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224835 · Cited by 25
Maguire, J., & Dhar, V. (2012) · Health Systems · doi:10.1057/hs.2012.20 · Cited by 23
Mangold, T. A., Rawls, W. N., Wall, B. M., Gosmanova, E. O., & Canada, R. B. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31816250e6 · Cited by 23
Dosing of insulin glargine in the treatment of type 2 diabetes
Barnett, A. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.018 · Cited by 22
Repurposing Metformin for Vascular Disease
Triggle, C. R., Marei, I., Ye, K., Ding, H., Anderson, T. J., Hollenberg, M. D., & Hill, M. A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220729154615 · Cited by 22
Mortality risk with sulphonylureas compared to metformin
Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12280 · Cited by 22
Phadwal, K., Koo, E., Jones, R. A., Forsythe, R. O., Tang, K., Tang, Q., CORCORAN, B. M., Caporali, A., & MacRae, V. E. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30887 · Cited by 24
Mata‐Cases, M. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000338 · Cited by 20
A review of mortality in type 2 diabetes mellitus
Asfandiyarova, N. S. (2015) · Diabetes Mellitus · doi:10.14341/dm6846 · Cited by 21
Krobot, K. J., Ferrante, S. A., Davies, M. J., Seck, T. L., Meininger, G. E., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.703134 · Cited by 18
Bennett, W. L., Balfe, L. M., & Faysal, J. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s1-a.1 · Cited by 17
Anselmino, M. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.07.003 · Cited by 17
Metformin Use in Patients With Diabetes Mellitus and Heart Failure: Friend or Foe?
Giamouzis, G., Triposkiadis, F. K., & Butler, J. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.12.007 · Cited by 17
Fazio, S., Mercurio, V., Fazio, V., Ruvolo, A., & Affuso, F. (2024) · Biomedicines · doi:10.3390/biomedicines12040806 · Cited by 17
Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death.
Pratipanawatr, T., Rawdaree, P., Chetthakul, T., Bunnag, P., Ngarmukos, C., Benjasuratwong, Y., Leelawatana, R., Kosachunhanun, N., Plengvidhya, N., Deerochanawong, C., et al. (2010) · PubMed · Cited by 15
Naidoo, P., Wing, J., & Rambiritch, V. (2016) · JMIR Research Protocols · doi:10.2196/resprot.5073 · Cited by 15
A blast from the past: To tame time with metformin
Xenos, D., Mecocci, P., & Boccardi, V. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111743 · Cited by 15
Xu, Z., Zhang, H., Wu, C., Zheng, Y., & Jiang, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.944902 · Cited by 14
Discovering Biological Mechanisms of Exceptional Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041204 · Cited by 14
Zhang, B., Cao, Y. Y., Qu, Z., Sun, Y., & Tian, X. (2024) · Endocrine · doi:10.1007/s12020-024-04012-x · Cited by 12
Metadata
- Authors
- Johnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R.
- Affiliations
- University of Alberta (CA)
- Institute of Health Economics (CA)
- Corresponding author
- Johnson, J. A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2005-03-21
- Volume
- 22
- Issue
- 4
- Pages
- 497-502
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1994294400
- Cited by
- 161
- References
- 31
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 7 · 2017: 8 · 2016: 6 · 2015: 11 · 2014: 11 · 2013: 11 · 2012: 11
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetic Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, type 2 diabetes, cardiovascular morbidity, cardiovascular mortality, macrovascular complications, cardiovascular hospitalization, oral antidiabetic drugs
- MeSH terms
- Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Epidemiologic Methods, Female, Hospitalization, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Saskatchewan, Sulfonylurea Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
